JPWO2020205331A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020205331A5
JPWO2020205331A5 JP2021557602A JP2021557602A JPWO2020205331A5 JP WO2020205331 A5 JPWO2020205331 A5 JP WO2020205331A5 JP 2021557602 A JP2021557602 A JP 2021557602A JP 2021557602 A JP2021557602 A JP 2021557602A JP WO2020205331 A5 JPWO2020205331 A5 JP WO2020205331A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
polypeptide sequence
variable region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557602A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527173A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/024432 external-priority patent/WO2020205331A1/en
Publication of JP2022527173A publication Critical patent/JP2022527173A/ja
Publication of JPWO2020205331A5 publication Critical patent/JPWO2020205331A5/ja
Pending legal-status Critical Current

Links

JP2021557602A 2019-03-29 2020-03-24 ヒト化抗クローディン18.2キメラ抗原受容体及びその使用 Pending JP2022527173A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962825955P 2019-03-29 2019-03-29
US62/825,955 2019-03-29
US201962859843P 2019-06-11 2019-06-11
US62/859,843 2019-06-11
US201962896758P 2019-09-06 2019-09-06
US62/896,758 2019-09-06
PCT/US2020/024432 WO2020205331A1 (en) 2019-03-29 2020-03-24 Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof

Publications (2)

Publication Number Publication Date
JP2022527173A JP2022527173A (ja) 2022-05-31
JPWO2020205331A5 true JPWO2020205331A5 (enExample) 2022-06-29

Family

ID=72667032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557602A Pending JP2022527173A (ja) 2019-03-29 2020-03-24 ヒト化抗クローディン18.2キメラ抗原受容体及びその使用

Country Status (12)

Country Link
US (1) US20220184126A1 (enExample)
EP (1) EP3947468A1 (enExample)
JP (1) JP2022527173A (enExample)
KR (1) KR20210144792A (enExample)
CN (1) CN113784980B (enExample)
AU (1) AU2020253792A1 (enExample)
BR (1) BR112021016673A2 (enExample)
CA (1) CA3132201A1 (enExample)
IL (1) IL286696A (enExample)
MX (1) MX2021011887A (enExample)
SG (1) SG11202109052YA (enExample)
WO (1) WO2020205331A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407828B2 (en) 2019-02-01 2022-08-09 Novarock Biotherapeutics, Ltd. Anti-CLauDiN 18 antibodies and methods of use thereof
WO2022122709A1 (en) * 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
CN115073606B (zh) * 2021-03-10 2025-05-02 上海莱馥医疗科技有限公司 一种靶向表达cldn 18.2的细胞的人源化嵌合抗原受体
CN113354739B (zh) * 2021-01-11 2022-08-23 上海莱馥医疗科技有限公司 一种靶向表达Claudin18.2细胞的嵌合抗原受体及其应用
CA3228137A1 (en) 2021-08-09 2023-02-16 Harbour Biomed (Shanghai) Co., Ltd Cldn18.2-targeting antibody, bispecific antibody and use thereof
AU2023276514A1 (en) * 2022-05-27 2024-12-05 Suzhou Immunofoco Biotechnology Co., Ltd Chimeric antigen receptor containing cldn18.2 single domain antibody and application thereof
US20240228610A9 (en) * 2022-10-10 2024-07-11 Medimmune, Llc Compositions and methods of treating cancer with chimeric antigen receptors targeting claudin 18.2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
UA128182C2 (uk) * 2012-11-13 2024-05-01 Біонтех Аґ Агенти для лікування експресуючих клаудин ракових захворювань
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药(上海)有限公司 抗密蛋白18a2的抗体及其应用
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
BR112020015479A2 (pt) * 2018-03-08 2020-12-08 Phanes Therapeutics, Inc. Anticorpos anticlaudina 18.2 e usos dos mesmos

Similar Documents

Publication Publication Date Title
JPWO2019173420A5 (enExample)
IL276830B1 (en) Anti-claudin 18.2 antibodies and their uses
JP2020501531A5 (enExample)
JP2009545325A5 (enExample)
CN103189392B (zh) ErbB3结合抗体
WO2019042119A1 (zh) 抗人cd47抗体及其用途
CN103030695B (zh) 抗c‑Met人源化抗体及含其的预防或治疗癌症用的药物组合物
JP2013502913A5 (enExample)
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
JP2013527761A5 (enExample)
RU2013152164A (ru) Анти-в7-н3-антитело
JPWO2019224711A5 (enExample)
CN115052896A (zh) 抗ror1抗体和组合物
TW200918556A (en) Treatment of tumors using specific anti-L1 antibody
CN103025760A (zh) 人源化egfr抗体
CN116940380A (zh) 使用grem1拮抗剂治疗疾病的方法
JPWO2020210067A5 (enExample)
JPWO2020205331A5 (enExample)
JP2019512210A5 (enExample)
WO2022110922A1 (zh) 抗SIRPα抗体或其抗原结合片段及应用
JPWO2019217145A5 (enExample)
JPWO2020210247A5 (enExample)
CN112805297B (zh) 抗人类pd-l1抗体及其用途
CN115190887A (zh) 结合cd47的抗原结合多肽及用途
CN114630839A (zh) 抗ox40抗体及其用途